Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Virology Journal
Published in: Virology Journal 1/2015

Open Access 01-12-2015 | Review

Schistosomiasis, hepatitis B and hepatitis C co-infection

Authors: Gasim I Gasim, Abdelhaleem Bella, Ishag Adam

Published in: Virology Journal | Issue 1/2015

Login to get access

Abstract

Background

Schistosomiasis is a significant health problem in more than 70 countries distributed between Africa, Asia and South America, with an infection rate of one in 30 individuals. Data on Schistosomiasis, Hepatitis B virus (HBV) and Hepatitis C virus (HCV) co-infection are scarce; however, there is a high prevalence in countries where schistosomiasis is endemic.

Methods

A systematic search was performed on published data from 1980–2014. Published papers in the databases Google, Medline, PubMed, and MiPc library were searched using the keywords epidemiology, pathogenesis and outcomes of HBV, HCV and schistosomiasis and data were extracted from the relevant studies.

Results

The prevalence of HBV/schistosomiasis co-infection in countries where schistosomiasis is endemic was high, ranging between 9.6 to approximately 64% in Egypt, and a maximum of 15.8% among hospitalized patients in Brazil. Concurrent infection between HBV and schistosomiasis is often associated with countries where schistosomiasis is endemic and may lead to chronic liver inflammation. Similarly, HCV infection rates in schistosomiasis populations range from 1% in Ethiopia reaching up to 50% in Egypt.

Conclusion

There is controversy regarding the effects of HBV and HCV on schistosomiasis and vice versa. Vaccination might be a solution to the era of schistosomiasis and co-infection with HBV and HCV.
Literature
1.
WHO: Status of Schistosomiasis endemic countries. Geneva: World Health Organization; 2012. apps.who.int/neglected_diseases/ ntddata/sch/sch.html.
2.
3.
Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis. 2006;6:411–25.CrossRefPubMed
4.
Barakat RM. Epidemiology of Schistosomiasis in Egypt: travel through time: review. J Adv Res. 2013;4:425–32.CrossRef
5.
Knopp S, Person B, Ame SM, Mohammed KA, Ali SM, Khamis IS, et al. Elimination of schistosomiasis transmission in Zanzibar: baseline findings before the onset of a randomized intervention trial. PLoS Negl Trop Dis. 2013;7:e2474.CrossRefPubMedCentralPubMed
6.
7.
Blanton RE, Salam EA, Kariuki HC, Magak P, Silva LK, Muchiri EM, et al. Population-based differences in Schistosomiasis mansoni and hepatitis C induced disease. J Infect Dis. 1859;2002:1644–9.
8.
Boisier P, Ramarokoto CE, Ravoniarimbinina P, Rabarijaona L, Ravaoalimalala VE. Geographic diffrerences in hepatosplenic complications of Schistosomiasis mansoni and explanatory factors of morbidity. Trop Med Int Health. 2001;6:699–706.CrossRefPubMed
9.
Dessein AJ, Hillaire D, Elwali NE, Marquet S, Mohamed-Ali Q, Mirghani A, et al. Severe hepatic fibrosis in Schistosoma mansoni infection is controlled by a major locus that is closely linked to the interferon-gamma receptor gene. Am J Hum Genet. 1999;65:709–21.CrossRefPubMedCentralPubMed
10.
King CH, Magak P, Abdel-Salam E, Ouma JH, Kariuki HC, Blanton E. Measuring morbidity in Schistosomiasis mansoni: relationship between image pattern, portal vein diameter and portal branch thickness in large-scale surveys using new WHO coding guidelines for ultrasound in schistosomiais. Trop Med Int Health. 2003;8:109–17.CrossRefPubMed
11.
Mohamed-Ali Q, Elwali NE, Abdelhameed AA, Mergani A, Rahoud S, Elagib KE, et al. Susceptibility to periportal (Symmers) fibrosis in human Schistosoma mansoni infections: evidence that intensity and duration of infection, gender and inherited factors are critical in disease progression. J Infect Dis. 1999;180:1298–306.CrossRefPubMed
12.
Elbaz T, Esmat G. Hepatic and Intestinal Schistosomiasis: Review. JAR. 2013;4:445–52.CrossRef
13.
Pereira LM, Domingues AL, Spinelli V, McFarlane IG. Ultrasonography of the liver and spleen in Brazilian patients with hepatosplenic Schistosomiasis and cirrhosis. Trans R Soc Trop Med Hyg. 1998;92:639–42.CrossRefPubMed
14.
Conceic¸a˜o MJ, Argento CA, Chagas VL, Takiya CM, Moura DC, Silva SC. Prognosis of Schistosomiasis mansoni patients infected with hepatitis B virus. Mem Inst Oswaldo Cruz. 1998;93:255–8.CrossRef
15.
El-Masry S, Lotfy M, El-Shahat M, Badra G. Serum laminin assayed by Slot-Blot-ELISA in patients with combined viral hepatitis C and schistosomiasis. Clin Biochem. 2006;39:652–7.CrossRefPubMed
16.
Kamal SM, Turner B, He Q, Rasenack J, Bianchi L, Al Tawil A, et al. Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis. Hepatology. 2006;43:771–9.CrossRefPubMed
17.
Kamal SM, Rasenack JW, Bianchi L, Al Tawil A, El Sayed KK, Peter T, et al. Acute hepatitis C without and with Schistosomiasis: correlation with hepatitis C-specific CD4(+) T-cell and cytokine response. Gastroenterology. 2001;121:646–56.CrossRefPubMed
18.
Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333–42.CrossRefPubMed
19.
Barnard H. Hepatitis C in Egypt, a iatrogenic epidemy. Ned Tijdschr Geneeskd. 2000;144:2024–5.PubMed
20.
El-Sayed HF, Abaza SM, Mehanna S, Winch PJ. The prevalence of hepatitis B and C infections among immigrants to a newly reclaimed area endemic for Schistosoma mansoni in Sinai, Egypt. Acta Trop. 1997;68:229–37.CrossRefPubMed
21.
Angelico M, Renganathan E, Gandin C, Fathy M, Profili MC, Refai W, et al. Chronic liver disease in the Alexandria governorate, Egypt: contribution of schistosomiasis and hepatitis virus infections. J Hepatol. 1997;26:236–43.CrossRefPubMed
22.
Aquino RT, Chieffi PP, Catunda SM, Araújo MF, Ribeiro MC, Taddeo EF, et al. Hepatitis B and C virus markers among patients with hepatosplenic mansonic schistosomiasis. Rev Inst Med Trop Sao Paulo. 2000;42:313–20.CrossRefPubMed
23.
Du H. Relationship between advanced schistosomiasis and HBV infection. Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi. 2013;25:115–7.PubMed
24.
Van-Lume DS, Albuquerque Mde F, Souza AI, Domingues AL, Lopes EP, Morais CN, et al. Association between Schistosomiasis mansoni and hepatitis C: systematic review. Rev Saude Publica. 2013;47:414–24.CrossRefPubMed
25.
Mudawi HM, Smith HM, Fletcher IA, Fedail SS. Prevalence and common genotypes of HCV infection in Sudanese patients with hepatosplenic schistosomiasis. J Med Virol. 2007;79:1322–4.CrossRefPubMed
26.
Li Y, Chen D, Ross AG, Burke ML, Yu X, Li RS, et al. Severe hepatosplenic schistosomiasis: clinicopathologic study of 102 cases undergoing splenectomy. Hum Pathol. 2011;42:111–9.CrossRefPubMed
27.
El-Esnawy NA, Al-Herrawy AZ. Seroprevalence of certain hepatitis viruses among Egyptian workers infected with schistosomiasis. J Egypt Public Health Assoc. 2000;75:357–66.PubMed
28.
Abdel-Rahman M, El-Sayed M, El Raziky M, Elsharkawy A, El-Akel W, Ghoneim H, et al. Co infection with hepatitis C virus and schistosomiasis: fibrosis and treatment response. World J Gastroenterol. 2013;19:2691–6.CrossRefPubMedCentralPubMed
29.
Al-Shamiri AH, Al-Taj MA, Ahmed AS. Prevalence and co-infections of Schistosomiasis/hepatitis B and C viruses among school children in an endemic area in Taiz, Yemen. Asian Pac J Trop Med. 2011;4:404–8.CrossRefPubMed
30.
Berhe N, Myrvang B, Gundersen SG. Intensity of Schistosoma mansoni, hepatitis B, age, and sex predict levels of hepatic periportal thickening/fibrosis (PPT/F): a large-scale community-based study in Ethiopia. Am J Trop Med Hyg. 2007;77:1079–86.PubMed
31.
Habib M, Mohamed MK, Abdel-Aziz F, Magder LS, Abdel-Hamid M, Gamil F, et al. Hepatitis C virus infection in a community in the Nile Delta: risk factors for seropositivity. Hepatology. 2001;33:248–53.CrossRefPubMed
32.
Silva JLA, Coelho MRCD, Souza VSB, Domingues ALC. Soroprevalência da hepatite C em pacientes com esquistossomose. Rev Para Med. 2008;22:27–32.
33.
Mohamoud YA, Mumtaz GR, Riome S, Miller D, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis. BMC Infect Dis. 2013;13:288.CrossRefPubMedCentralPubMed
34.
Silva JLA, Souza VSB, Vilella TAS, Domingues ALC, Coêlho MRCD. Marcadores sorológicos do VHB e VHC em pacientes com esquistossomose mansônica na forma hepatoesplênica. Arq Gastroenterol. 2011;48:124–30.CrossRefPubMed
35.
Edris A, Nour MO, Zedan OO, Mansour AE, Ghandour AA, Omran T. Seroprevalence and risk factors for hepatitis B and C virus infection in Damietta Governorate. Egypt East Mediterr Health J. 2014;20:605–13.
36.
Wahib AA, Masoud AA, Halem AA, Haseeb AN, Hassan AR, Darwish MA, et al. Cell mediated immune response in chronic liver diseases: schistosomal, viral and neoplastic. J Egypt Soc Parasitol. 1998;28:929–39.PubMed
37.
Edwards MJ, Buchatska O, Ashton M, Montoya M, Bickle QD, Borrow P. Reciprocal immunomodulation in a schistosome and hepatotropic virus coinfection model. J Immunol. 2005;175:6275–85.CrossRefPubMed
38.
Chen L, Liu WQ, Lei JH, Guan F, Li MJ, Song WJ, et al. Chronic Schistosoma japonicum infection reduces immune response to vaccine against hepatitis B in mice. PLoS One. 2012;7:e51512.CrossRefPubMedCentralPubMed
39.
40.
Elrefaei M, El-Sheikh N, Kamal K, Cao H. HCV-specific CD27–CD28- memory T cells are depleted in hepatitis C virus and Schistosoma mansoni co-infection. Immunology. 2003;110:513–8.CrossRefPubMedCentralPubMed
41.
Makhlouf LM, Serwah Ael H, Abd El-Hamid Ael D, Hussein EM, Saad RM. INF-gamma, IL-5 and IgE profiles in chronic Schistosomiasis mansoni Egyptian patients with or without hepatitis C infection. J Egypt Soc Parasitol. 2006;36:177–96.PubMed
42.
Emam EA, Emam M, Shehata AE, Emara M. Impact of Schistosoma mansoni co-infection on serum profile of interferon-gamma, interleukin-4 and interleukin-10 in patients with chronic hepatitis C virus infection. Egypt J Immunol. 2006;13:33–40.PubMed
43.
El-Awady MK, Youssef SS, Omran MH, Tabll AA, El Garf WT, Salem AM. Soluble egg antigen of Schistosoma Haematobium induces HCV replication in PBMC from patients with chronic HCV infection. BMC Infect Dis. 2006;6:91.CrossRefPubMedCentralPubMed
44.
Elsammak MY, Al-Sharkaweey RM, Ragab MS, Amin GM, Kandil MH. In Egyptians, a mutation in the lymphotoxin-alpha gene may increase susceptibility to hepatitis C virus but not that to Schistosomal infection. Ann Trop Med Parasitol. 2008;102:709–16.CrossRefPubMed
45.
Abbas OM, Abdel-Rahman MH, Omar NA, Badran HM, Amir EM. Interleukin-10 promoter polymorphisms in hepatitis C patients with and without Schistosoma mansoni co-infection. Liver Int. 2009;29:1422–30.CrossRefPubMed
46.
Hammad HA, el Fattah MM, Moris M, Madina EH, el Abbasy AA, Soliman AT. Study on some hepatic functions and prevalence of hepatitis B surface antigenaemiain Egyptian children with Schistosomal hepatic fibrosis. J Trop Pediatr. 1990;36:126–7.CrossRefPubMed
47.
Al-Freihi HM. Prevalence of hepatitis B surface antigenemia among patients with Schistosoma mansoni. Ann Saudi Med. 1993;13:121–5.PubMed
48.
Larouze B, Dazza MC, Gaudebout C, Habib M, Elamy M, Cline B. Absence of relationship between Schistosoma mansoni and hepatitis B virus infection in the Qalyub Governate, Egypt. Ann Trop Med Parasitol. 1987;81:373–5.PubMed
49.
Ye XP, Fu YL, Anderson RM, Nokes DJ. Absence of relationship between Schistosoma japonicum and hepatitis B virus infection in the Dongting lake region, China. Epidemiology and Infection. 1998;121:193–5.CrossRefPubMedCentralPubMed
50.
Andrade ZA, Berthillon P, Paraná R, Grimaud JA, Trépo C. Schistosomiasis mansoni and viral B hepatitis in woodchucks. J Hepatol. 2001;34:134–9.CrossRefPubMed
51.
52.
McClary H, Koch R, Chisari FV, Guidotti LG. Inhibition of hepatitis B virus replication during Schistosoma mansoni infection in transgenic mice. J Exp Med. 2000;192:289–94.CrossRefPubMedCentralPubMed
53.
54.
Andrade JR, Silva LD, Guimarães CM, Bassetti-Soares E, Cambraia RD, Couto OF, et al. Chronic hepatitis B and liver schistosomiasis: a deleterious association. Trans R Soc Trop Med Hyg. 2014;108:159–64.CrossRefPubMed
55.
Lundy SK, Lukacs NW. Chronic schistosome infection leads to modulation of granuloma formation and systemic immune suppression. Front Immunol. 2013;4:39.CrossRefPubMedCentralPubMed
56.
Bassily S, Strickland GT, Abdel-Wahab MF, Esmat GE, Narooz S, el-Masry NA, et al. “Efficacy of hepatitis B vaccination in primary school children from a village endemic for Schistosoma mansoni,”. J Infect Dis. 1992;166:265–8.CrossRefPubMed
57.
Mohamed A, Elsheikh A, Ghandour Z, Al Karawi M. Impact of hepatitis C virus infection on Schistosomal liver disease. Hepatogastroenterology. 1998;45:1492–6.PubMed
58.
Gad A, Tanaka E, Orii K, Rokuhara A, Nooman Z, Serwah AH, et al. Relationship between hepatitis C virus infection and Schistosomal liver disease: not simply an additive effect. J Gastroenterol. 2001;36:753–8.CrossRefPubMed
59.
Allam WR, Barakat A, Zakaria Z, Galal G, Abdel-Ghafar TS, El-Tabbakh M, et al. Schistosomiasis does not affect the outcome of HCV infection in genotype 4-infected patients. Am J Trop Med Hyg. 2014;90:823–9.CrossRefPubMed
60.
Keang H, Odermatt P, Odermatt-Biays S, Cheam S, Degremont A, Hatz C. Liver morbidity due to Schistosoma mekongi in Cambodia after seven rounds of mass drug administration. Trans R Soc Trop Med Hyg. 2007;101:759–65.CrossRefPubMed
61.
Huang LH, Qiu YW, Hua HY, Niu XH, Wu PF, Wu HY, et al. The efficacy and safety of entecavir in patients with advanced Schistosomiasis co-infected with hepatitis B virus. Int J Infect Dis. 2013;17:e606–609.CrossRefPubMed
62.
Draz HM, Mahmoud SS, Ashour E, Shaker YM, Wu CH, Wu GY. Effects of PEG-interferon-alpha-2A on Schistosoma mansoni infection in mice. J Parasitol. 2010;96:703–8.CrossRefPubMed
63.
Derbala MF, Al Kaabi SR, El Dweik NZ, Pasic F, Butt MT, Yakoob R, et al. Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: impact of bilharziasis and fibrosis stage. World J Gastroenterol. 2006;12:5692–8.PubMedCentralPubMed
64.
Tian Z, Wang SP, Zeng SH, Liu XQ, Gao DM, Feng QM, et al. Characterization and vaccination of two novel Schistosoma japonicum genes screened from a cercaria cDNA library. Parasitol Res. 2012;110:403–9.CrossRefPubMed
65.
Qiu C, Liu S, Hong Y, Fu Z, Wei M, Ai D, et al. Molecular characterization of thyroid hormone receptor beta from Schistosoma japonicum and assessment of its potential as a vaccine candidate antigen against Schistosomiasis in BALB/c mice. Parasit Vectors. 2012;13:5–172.
66.
Gray DJ, Li YS, Williams GM, Zhao ZY, Harn DA, Li SM, Ren MY, Feng Z, Guo FY, Guo JG, Zhou J, Dong YL, Li Y, Ross AG, McManus DP. A multi-component integrated approach for the elimination of Schistosomiasis in the People's Republic of China: design and baseline results of a 4-year cluster-randomised intervention trial. Int J Parasitol. 2014 pii, S0020-751900136-2.
67.
Espíndola MS, Frantz FG, Soares LS, Masson AP, Tefé-Silva C, Bitencourt CS, et al. Combined immunization using DNA-Sm14 and DNA-Hsp65 increases CD8+ memory T cells, reduces chronic pathology and decreases egg viability during Schistosoma mansoni infection. BMC Infect Dis. 2014;14:263.CrossRefPubMedCentralPubMed
68.
Zhang W, Ahmad G, Le L, Rojo JU, Karmakar S, Tillery KA, et al. Longevity of Sm-p80-specific antibody responses following vaccination with Sm-p80 vaccine in mice and baboons and transplacental transfer of Sm-p80-specific antibodies in a baboon. Parasitol Res. 2014;113:2239–50.CrossRefPubMed
69.
70.
Garcia A, Fernandez S, Toro F, De Sanctis JB. An Overview Of Hepatitis C Vaccines. Recent Pat Inflamm Allergy Drug Discov. 2014;8:85–91.PubMed
71.
Baldo V, Bonanni P, Castro M, Gabutti G, Franco E, Marchetti F, et al. Combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b vaccine; Infanrix™ hexa: Twelve years of experience in Italy. Hum Vaccin Immunother. 2014;10:129–37.CrossRefPubMed
72.
Vesikari T, Forstén A, Desole MG, Ferrera G, Caubet M, Mesaros N, et al. A combined Haemophilus influenzae type B Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when coadministered with diphtheria, tetanus, acellular pertussis hepatitis B-inactivated poliovirus at 3, 5 and 11 months of age: results of an open, randomized, controlled study. Pediatr Infect Dis J. 2013;32:521–9.CrossRefPubMed
Metadata
Title
Schistosomiasis, hepatitis B and hepatitis C co-infection
Authors
Gasim I Gasim
Abdelhaleem Bella
Ishag Adam
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2015
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-015-0251-2

Other articles of this Issue 1/2015

Virology Journal 1/2015 Go to the issue

Research

A new duck circovirus sequence, detected in velvet scoter (Melanitta fusca) supports great diversity among this species of virus

Research

Healthy rabbits are susceptible to Epstein-Barr virus infection and infected cells proliferate in immunosuppressed animals

Research

Engineering and expression of a human rotavirus candidate vaccine in Nicotiana benthamiana

Short report

Diverse origins of hepatitis C virus in HIV co-infected men who have sex with men in Hong Kong

Research

Synergistic inhibition of avian leukosis virus subgroup J replication by miRNA-embedded siRNA interference of double-target

Research

Association between TNFAIP3 nonsynonymous single-nucleotide polymorphism rs2230926 and chronic hepatitis B virus infection in a Chinese Han population

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits